» Articles » PMID: 27009263

Protein Biomarkers Discriminate Leishmania Major-infected and Non-infected Individuals in Areas Endemic for Cutaneous Leishmaniasis

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2016 Mar 25
PMID 27009263
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A successful host immune response to infection is dependent upon both innate and adaptive immune effector mechanisms. Cutaneous leishmaniasis results in an adaptive Th1 CD4(+) T cell response that efficiently clears the parasite, but may also result in scaring. However the role of innate mechanisms during parasite clearance remains less well defined.

Methods: We examined a unique cohort of individuals, living in a Leishmania major endemic region, that were stratified among 3 distinct clinical groups in a cross-sectional study. Specifically, patients were classified either as healed (n = 17), asymptomatic (23), or naïve to infection (18) based upon the classical Leishmanin Skin Test (LST) and the presence or absence of scars. Utilizing a multiplexed immunoassay approach we characterized the induced cytokine and chemokine response to L. major.

Results: A subset of innate immune molecules was induced in all groups. By contrast, T cell-associated cytokines were largely induced in exposed groups as compared to L. major-infection naïve individuals. Two exceptions were IL-17A and IL-12p70, induced and not induced, respectively, in naïve individuals. In addition, GM-CSF was more strongly induced in healed patients as compared to the other two groups. Surprisingly an IL-13 response was the best cytokine for classifying previously infected donors.

Conclusions: Exploratory data analysis, utilizing principle component analysis (PCA), revealed distinct patient clusters of the healed and naïve groups based on the most differentially induced proteins. Asymptomatic previously infected individuals were more difficult to assign to a particular cluster based on these induced proteins. Analysis of these proteins may enable the identification of biomarkers associated with disease, leading to a better understanding of the protective mechanisms of immune response against leishmaniasis.

Citing Articles

Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics.

Yeshi K, Ruscher R, Loukas A, Wangchuk P Front Parasitol. 2025; 1():984152.

PMID: 39816468 PMC: 11731824. DOI: 10.3389/fpara.2022.984152.


A Prospective cohort study of zoonotic cutaneous leishmaniasis in tunisia: Clinical and Immunological features and immune correlates of protection.

Naouar I, Kammoun Rebai W, Salah A, Bouguerra H, Toumi A, Hamida N PLoS Negl Trop Dis. 2023; 17(12):e0011784.

PMID: 38064516 PMC: 10732404. DOI: 10.1371/journal.pntd.0011784.


Potential biomarkers of immune protection in human leishmaniasis.

Nateghi Rostami M, Khamesipour A Med Microbiol Immunol. 2021; 210(2-3):81-100.

PMID: 33934238 PMC: 8088758. DOI: 10.1007/s00430-021-00703-8.


Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

Hamrouni S, Bras-Goncalves R, Kidar A, Aoun K, Chamakh-Ayari R, Petitdidier E PLoS Negl Trop Dis. 2020; 14(3):e0008093.

PMID: 32176691 PMC: 7098648. DOI: 10.1371/journal.pntd.0008093.


Label-free quantitative proteomic analysis reveals potential biomarkers for early healing in cutaneous leishmaniasis.

Montoya A, Lopez M, Velez I, Robledo S PeerJ. 2019; 6:e6228.

PMID: 30648003 PMC: 6330957. DOI: 10.7717/peerj.6228.


References
1.
von Stebut E, Ehrchen J, Belkaid Y, Kostka S, Molle K, Knop J . Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med. 2003; 198(2):191-9. PMC: 2194079. DOI: 10.1084/jem.20030159. View

2.
Ajdary S, Alimohammadian M, Eslami M, Kemp K, Kharazmi A . Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun. 2000; 68(4):1760-4. PMC: 97345. DOI: 10.1128/IAI.68.4.1760-1764.2000. View

3.
Sassi A, Louzir H, Ben Salah A, Mokni M, Ben Osman A, Dellagi K . Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol. 1999; 116(1):127-32. PMC: 1905205. DOI: 10.1046/j.1365-2249.1999.00844.x. View

4.
Spath G, Beverley S . A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol. 2001; 99(2):97-103. DOI: 10.1006/expr.2001.4656. View

5.
Faria D, Gollob K, Barbosa Jr J, Schriefer A, Machado P, Lessa H . Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun. 2005; 73(12):7853-9. PMC: 1307048. DOI: 10.1128/IAI.73.12.7853-7859.2005. View